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Alzheimer's riskNeuroimaging biomarkers that precede cognitive decline have the potential to aid early diagnosis of
Alzheimer's disease (AD). A body of diffusion tensor imaging (DTI) work has demonstrated declines in white
matter (WM) microstructure in AD and its typical prodromal state, amnestic mild cognitive impairment. The
present review summarizes recent evidence suggesting that WM integrity declines are present in individuals
at high AD-risk, prior to cognitive decline. The available data suggest that AD-risk is associated with WM
integrity declines in a subset of tracts showing decline in symptomatic AD. Speciﬁcally, AD-risk has been
associated with WM integrity declines in tracts that connect gray matter structures associated with memory
function. These tracts include parahippocampal WM, the cingulum, the inferior fronto-occipital fasciculus,
and the splenium of the corpus callosum. Preliminary evidence suggests that some AD-risk declines are
characterized by increases of radial diffusivity, raising the possibility that a myelin-related pathology may
contribute to AD onset. These ﬁndings justify future research aimed at a more complete understanding of the
neurobiological bases of DTI-based declines in AD. With continued reﬁnement of imaging methods, DTI holds
promise as a method to aid identiﬁcation of presymptomatic AD. This article is part of a Special Issue entitled:
Imaging Brain Aging and Neurodegenerative disease.g Brain Aging and Neurodegen-
tucky Medical Center, 800 Rose
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is themost common form of dementia. AD
initially impairs memory function, but gradually progresses to affect
other domains of cognition. Eventually AD results in the inability to
communicate, recognize family members, or function independently.
Recent estimates suggest that AD affects 4.5 million Americans and is
projected to affect13.2 millionby2050 [1]. There is nowstrongevidence
that signiﬁcant Alzheimer's neuropathology is present years before the
appearance of clinical symptoms associated with amnestic mild
cognitive impairment (aMCI) or AD [2,3]. Consistent with this evidence,
by the time of diagnosis, the AD brain shows widespread neural loss,
cortical thinning, ventricular enlargement and demyelination.
At present, AD treatment options are limited. Currently available
pharmacological therapies slow cognitive decline only for about a year.
Although new interventions are under investigation, they are likely to
bemore successful by preventing rather than reversing neurodegenera-tion. There is an emerging consensus that the focus of AD research
shouldmove toward identiﬁcation of presymptomatic biomarkers [4,5].
Neuroimaging is capable of playing an important role in the develop-
ment of presymptomatic AD biomarkers. Indeed, newly proposed
criteria for AD and its preclinical states support the use of imaging and
other biomarkers to enhance early detection in those likely to develop
clinical AD (http://www.alz.org/research/diagnostic_criteria/).
There is thus a strong rationale for neuroimaging studies inves-
tigating cognitively normal seniors at high AD-risk based on genetics
and/or family history. As other reviews in this issue will summarize,
several methodologies have been applied to asymptomatic persons to
assess the brain at AD risk, including resting glucose positron emission
tomography, amyloid imaging, and functional and structural magnetic
resonance imaging. The majority of research conducted in presymp-
tomatic persons to date has focused on gray matter (GM) neurode-
generation. This is because the neuropathology of AD in GM brain
regions is well established: amyloid plaques and intracellular neu-
roﬁbrillary tangles initially target medial temporal lobe (MTL) GM,
resulting in prominent neurodegeneration of the hippocampus and
entorhinal cortex (ERC) [6,7].
However, ever since the work of Brun and Englund [8], it has
been known that microscopic WM changes are also present in AD.
These authors reported a partial loss of myelin sheaths, axons, and
417B.T. Gold et al. / Biochimica et Biophysica Acta 1822 (2012) 416–422oligodendroglial cells together with a mild glial reaction. The advent of
diffusion tensor imaging (DTI) has made it possible to explore the
possibility ofWMmicrostructural alterations in vivo. DTI-baseddeclines
have been shown to contribute to age-related cognitive declines [9–11],
suggesting they are functionally signiﬁcant to the study of healthy and
pathological forms of aging. For a review of DTI-based declines
associated with normal aging see Madden et al. (this issue). Recent
reviews have summarized evidence that WMmicrostructural integrity
is decreased in AD and aMCI [12,13]. The purpose of this review is to
summarize evidence suggesting that WM microstructural integrity is
also altered in cognitively normal individuals at high AD-risk.
We beginwith a description of the twomost common risk factors for
late-onset AD: the epsilon-4 allele of the APOE gene, and family history
of AD. We then provide a brief description of DTI and its most typical
metrics used to assess WM integrity. Next, we review the patterns of
WM integrity declines associated with AD-risk and compare them to
declines associated with symptomatic AD.We then discuss some of the
potential neurobiological bases of DTIﬁndings. Finally,we conclude that
while DTI holds promise as a contributor to early AD diagnosis, future
research is required to determine the neurobiological bases of DTI
changes and the validity of DTI as a biomarker of presymptomatic AD.
2. Risk factors associated with Alzheimer's disease
2.1. Apolipoprotein E
Apolipoprotein E (APOE) confers the greatest genetic risk for late-
onset AD among at least six other genes recently discovered or
conﬁrmed [14]. APOE is a glycoprotein and is involved in the transport
of cholesterol and other lipids through cell membranes. In the brain,
APOE is mainly produced by glial cells and is thought to be involved in
neuronal growth and regeneration [15]. A polymorphism in the gene
encoding APOE is known to confer an increase in the susceptibility to
late-onset AD. Genetic polymorphisms are allelic variations found
frequently in the population. There are at least three slightly different
alleles of the APOE gene, which is located on chromosome 19. The
major alleles are epsilon-2, -3, and -4. The most common allele is
epsilon-3, which is found in more than half of the general population.
Possession of the APOE-4 allele is associated with an increased risk
of late-onset AD [16]. In addition, there is a dose-dependency of
APOE-4, such that individuals with two APOE-4 alleles (the 4/4
genotype), are at greater AD-risk than individuals with only a single
copy (the 3/4 genotype) [17]. Those individuals those with two e4
alleles have up to 20 times the risk of developing AD, mainly through
an effect lowering the age of onset by approximately ten years. The
role of APOE in the development of AD is not yet established. One
theory is that APOE-4 may result in decreased plasticity of neuronal
synapses, and decreased ability to repair damaged neurons compared
to other allelic variants [18].
2.2. Family history of Alzheimer's disease
Not all people with AD have the APOE-4 allele, and not all people
who have this allele will develop AD. A second signiﬁcant risk factor
for late-onset AD is family history. Individuals with a ﬁrst-degree
relative affected with AD have been found to have between a 4 to 10
fold increase in AD-risk [19–21]. Further, in those above the age of 70,
the risk increases to more than 40% for those with two parents that
have been diagnosed with AD. The APOE-4 gene accounts for ap-
proximately 50% of this genetic variance.
This leaves50%of thevariance in the linkbetween family history and
AD unaccounted for, suggesting the existence of other genetic risk
factors for AD. Several other potential genes are currently under inves-
tigation including SORL1 on chromosome 11, A2M on chromosome 12,
GST01 and GST02 on chromosome 10, and GAB2 on chromosome 11
[22]. Recently four new genes have been identiﬁed in a large genome-wide association study (MS4A, CD2AP, CD33, and EPHA1) and twomore
supported (BIN1 and ABCA7), conﬁrming late-onset AD as a true poly-
genetic disorder [14]. At the next level of complexity signiﬁcant
interactions of genes CR1, CLU and PICALM with APOE genotypes have
been described [23].
In addition to genetic variables, the association between environ-
mental and lifestyle variables (e.g., diet, exercise, cognitive stimulation)
andAD-risk is also being explored. Nevertheless, at present, APOE-4 and
family history of dementia represent the strongest established risk
factors for late-onset AD.
3. Diffusion tensor imaging
The advent of DTI has allowed for assessment ofWMmicrostructure
in vivo. DTI is an extended form of diffusion-weighted tensor trace
imaging that is sensitized to the motion of water molecules as they
interactwithin tissues, thus reﬂecting characteristics of their immediate
structural surroundings [24,25]. In DTI, a series of diffusion gradients is
applied to determine three independent directional vectors, fromwhich
the 3-dimensional shape of diffusion can be generated for each voxel.
Patterns of water diffusion vary systematically across different
compartments of the brain (Fig. 1). Water diffusion is equal in all
directions (isotropic) in the ventricles because it is unconstrained by
biological barriers. In contrast, water diffusion is more directional
(anisotropic) in the brain's WM due to its internal ﬁbrous structure.
For example, water diffuses up to seven times more rapidly along the
direction parallel to the longitudinal axis of axonal orientation com-
pared to the direction orthogonal to the main ﬁber direction [26,27].
Structures that restrict water movement perpendicular to axonal
orientation include myelin sheaths, axonal membranes, and neuro-
ﬁlaments within the axoplasm [28]. Within WM, water diffusion is
highest in tracts that contain the largest numbers of ﬁbers running in
parallel, such as the corpus callosum [29].
4. Measures of diffusion tensor imaging
The four most commonly used measures of DTI, and the equations
used to compute them, are displayed in Fig. 2. These measures are
derived from three eigenvectors that deﬁne the diffusion ellipsoid in
each voxel. The eigenvectors are calculated for each voxel by diag-
onalizing each voxel's diffusion tensor. The eigenvalues are the
magnitude (length) of these three eigenvectors and represent themag-
nitude of diffusion, and diffusion coefﬁcient, in the three principle
directions. Axial diffusivity (DA) reﬂects the diffusion coefﬁcient along
the direction of maximal ‘apparent’ diffusion (λ1), whereas radial
diffusivity (DR) reﬂects the average diffusion coefﬁcients along the two
perpendicular directions ((λ2+λ3)/2) [30]. Mean diffusivity (MD) is a
scalar measure of the total amount of diffusion within a voxel and is
computed as an average of all three eigenvalues of the diffusion tensor
[25]. Finally, fractional anisotropy (FA) is computed as a weighted
average of the three eigenvalues of the diffusion tensor in order to
represent the fraction of the tensor deﬁnedby anisotropic diffusion [25].
5. What the measures reﬂect
Diffusion properties associated with these different DTI measures
can be interpreted as reﬂecting different structural contributions toWM
integrity. Fractional anisotropy (FA) reﬂects the coherence of the
orientation (or directionality) ofwater diffusion, independent of its rate,
and is thought to provide an overall assessment of WM integrity [25].
MDdepends on the density of physical obstructions such asmembranes
and the resultant distribution of water molecules between different cell
compartments [28]. Higher MD values indicate increased diffusion
which suggests tissue breakdown and increased brain water content
[25]. Compared to FA and MD, DTI-based component diffusivities (DA
and DR) provide more speciﬁc information about the integrity of axons
Fig. 1. Schematic of DTI-based water diffusion patterns in isotropic and anisotropic environments. Water molecules are represented in blue. (A) In compartments with minimal
biological barriers (e.g., ventricles; represented by a sphere), water molecules are free to diffuse equally in all directions (isotropic diffusion). (B) In compartments with an internal
ﬁbrous structure (e.g., white matter; represented here by a cylinder), biological barriers such as the axonmembrane, myelin sheath, microtubules, and neuroﬁlaments limit diffusion
in one ormore directions (anisotropic diffusion). (C)Within white matter, anisotropic diffusion is highest in tracts with highly organized, coherently oriented axonal bundles such as
those found in the corpus callosum (represented here by cylinders). The trajectory of the water molecules is along the longitudinal axis of the axon bundles.
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with loss of myelin in animal studies of experimentally induced myelin
loss [30–32]. In contrast, a decrease in DA has been reported in both
rodents and humans with axonal damage associated with axonal
swelling, fragmentation and organelle accumulations [32,33].
6. WM integrity declines associated with high AD-risk
We identiﬁed seven DTI studies that have explored the role of
APOE4, and/or familial history of AD, on WM microstructure [34–40].
Our searchwas conducted usingMEDLINE andwas restricted to English
articles and human subjects. Search terms were ‘diffusion tensor’
alternatively paired with one of the following: ‘APOE’, ‘presymptomatic
Alzheimer's’, ‘family history Alzheimer's’, or ‘Alzheimer's risk’. The
studies identiﬁed used a variety of different analyses including manual
region-of-interest (ROI) tracing, voxel-based morphometry implemen-Fig. 2. Calculating diffusion. Axial diffusivity (DA), radial diffusivity (DR), mean diffusivity (M
Three principle eigenvectors and their associated eigenvalues are used to calculate each co
eigenvectors. (C) Geometric representations of low, moderate, and high FA values.ted in SPM software, or tract-based spatial statistics (TBSS) implemen-
ted in FSL software. The DTI analysis techniques, sample sizes, and
reported regions showing decreased WM integrity (deﬁned as
decreased FA and/or increased MD) in individuals at high AD-risk are
reported in Table 1.
Decisions about which analysis techniques (i.e. ROI-based versus
whole-brain, or a combination of both) and which software package to
use are of course based on multiple variables such as theoretical
approach (i.e. hypothesis driven versus exploratory) and familiarity
with speciﬁc software packages. In our studies, and those of several
other groups, the tract-based spatial statistics (TBSS) technique was
used in order to explore group differences in across the brain'sWM. The
TBSS method has several advantages compared to other whole-brain
analysis techniques including improved registrationofWMtracts across
subjects [41] and the lack of a need to apply an arbitrary smoothing
kernel, which can produce different results based on kernel size [42].D), and fractional anisotropy (FA) are calculated by modeling the tensor in each voxel.
mponent. (A) Equations used to calculate DA, DR, MD, and FA. (B) The three principle
Table 1
White matter tracts showing integrity declines (FA decreases and/or MD increases) in
AD risk studies.
Study Technique N WM tract
Nierenberg et al., 2005 ROI 29 PHW
Persson et al., 2006 ROI, SPM-VBM 60 CC, CING/IFOF, HC
Honea et al., 2009 FSL-TBSS 53 PHW
Gold et al., 2010 FSL-TBSS 57 CING, FORNIX, CC, ILF, IFOF/UNC
Smith et al., 2010 FSL-TBSS 65 PHW, CING, CC, ILF/IFOF
Bendlin et al., 2010 SPM-VBM 136 HC, CING, IFOF/UNC, CC
Heise et al., in press FSL-TBSS 39 CING, CC, SLF
Notes: ROI, region of interest; SPM-VBM, statistical parametric mapping-voxel based
morphometry; FSL-TBSS, tract-based spatial statistics; CC, corpus callosum; CING,
cingulum; HC, hippocampus (gray matter); PHW, parahippocampal white matter; UNC,
uncinate fasciculus; SLF, superior longitudinal fasciculus; ILF, inferior longitudinal
fasciculus; IFOF, inferior fronto-occipito fasciculus.
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integrity predominantly in tracts with direct or secondary connec-
tions to MTL structures (Table 1). Variability in the speciﬁc affected
tracts reported in different studies is likely to be due to differences in
subject characteristics and analysis techniques. Nevertheless, multiple
AD-risk studies have reported reduced WM integrity in parahippo-
campal WM [34,36,37], the cingulum [35,37–40], the inferior fronto-
occipital fasciculus/uncinate fasciculus (IFOF/UNC) [35,37,38,40] and
corpus callosum [35,37–40].
Results from one of our AD-risk studies [37] are presented in Fig. 3.
We observed a clearly delineated decrease in FA in the inferior
temporal lobe WM bilaterally (ILF/IFOF). This decrease has a strong
linear spatial character suggesting involvement of a speciﬁc group of
white matter ﬁbers bridging the amygdala/hippocampal head region
anteriorly and the ventral visual association areas posteriorly. We also
found signiﬁcant FA decreases in the splenium of the corpus callosum,
the cingulum bundle, and the IFOF anteriorly. The downward cur-
vature of the FA reductions in the IFOF is characteristic of frontal
portions of this pathway, which parallels the uncinate fasciculus in
part of its course. In general our ﬁndings were more robust in the
temporal and frontal regions than in parietal lobes, andmore spatially
coherent in the ventral visual association regions, medial temporal
lobe, cingulum and frontal lobe than in the parietal lobe or occipital
lobe.
As noted above, not all individuals at genetic/familial risk for late-
onset ADwill actually develop AD. In contrast, the early-onset, familial
autosomal dominantly (FAD) inherited form of AD, while very rare, is
nearly 100% penetrant. The future development of AD can be reliably
predicted in individuals with FAD-related genetic mutations. At pres-
ent, however, only one study has assessed WM integrity in pre-
symptomatic FAD mutation carriers. Using ROI analyses, Ringman et
al. [43] found decreased WM integrity in the fornix and in WM of theFig. 3. Regions of decreased fractional anisotropy in normal, high AD-risk subjects. The
anisotropy (FA) image. The registered average FA skeleton is represented in green. Warmer
group compared to low AD-risk group. The patterns of FA decreases indicated by the arro
occipital fasciculus/uncinate fasciculus (B). Decreased FA in the high AD-risk group was also
cingulum bundle on the left (C; double arrowheads).
Adapted from Smith et al. (2010) with permission.ventral frontal cortex. Interestingly, several of the AD-risk studies
summarized above have also reported decreased WM integrity in
the fornix [38] and ventral frontal cortex WM near the IFOF/UNC
[35,37,38,40]. Future DTI studies are required to determine the sen-
sitivity and speciﬁcity of integrity declines in these WM tracts in
predicting AD in normal seniors.
7. Comparison with symptomatic AD results
Results from DTI studies of symptomatic AD have demonstrated
that reduced FA and/or increased MD is fairly widespread by the time
of AD diagnosis (for a review see Refs. [12,13]). However, the most
prominent decreases have been reported in tracts with direct or
secondary connections to MTL structures, including tracts showing
decreases in AD-risk studies (parahippocampal WM, the cingulum,
the IFOF/UNC, and the corpus callosum) [44–50]. Results from studies
exploring DTI changes in aMCI have tended to report WM integrity
changes which generally parallel changes in AD [12,13]. However, the
precise location of WM integrity declines tends to be more variable
across aMCI studies than AD studies, whichmay be in part attributable
to differences in diagnostic criteria used for aMCI.
A recent study that examined normal control, MCI and AD subjects
found the strongest WM alterations in cingulum bundle, uncinate
fasciculus, corpus callosum and the SLF. An interesting observation
from this study was that increased “cigar-like” ellipsoid anisotropy
was found in regions of crossing ﬁbers in deep white matter,
attributed to relative preservation of well-myelinated motor ﬁbers
with alteration of myelin in crossing association bundles [51]. This
study did not examine AD risk factors in the normal control subjects.
In summary, studies of normal individuals at high AD-risk have
reported WM integrity declines in a sub-set of tracts affected in
symptomatic AD including parahippocampal WM, caudal portions of
the cingulum, the IFOF, and posterior portions of the corpus callosum.
A few studies have also reported reduced WM integrity in the fornix.
Importantly, these WM tracts connect structures involved in episodic
memory function, the hallmark impairment of early AD. Speciﬁcally,
the caudal portion of the cingulum contains ﬁbers that connect the
posterior cingulate cortex with the entorhinal cortex and hippocam-
pus [52]. The fornix connects the hippocampus with the septal nuclei
in the basal frontal region, the mamillary bodies of the hypothalamus,
and the anterior nuclei of the thalamus. The IFOF contains connections
between occipital visual regions and ventrolateral prefrontal cortex, a
region with an established role in memory encoding [53]. Posterior
portions of the corpus callosum connect bilateral parietal regions,
including the precuneus and retrosplenial regions known to contrib-
ute to memory function [54]. Finally, additional widespread WM
integrity reduction in long association ﬁbers has recently been de-
scribed in MCI and AD.anatomic underlay used for illustration is the MNI-space registered target fractional
colors on red-orange scale indicate higher t-values of FA decreases for the high AD-risk
wheads correspond to the inferior fronto-occipital fasciculus (A) and inferior fronto-
evident in the splenium of the corpus callosum (C; single arrowhead) and the posterior
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Of the AD-risk studies conducted to date, four have explored
component diffusivities in addition to FA and MD [34,38–40]. In each
of the studies except one [39], AD-risk was associated with increased
DR in many of the regions showing decreased FA. In particular,
increased DR has been reported in medial temporal lobe WM [34,40]
and in the cingulum and IFOF/UNC [38,40]. In contrast, minimal or no
signiﬁcant changes in DA associated with AD-risk were reported in
any of these AD-risk studies.9. Comparison with symptomatic AD results
We were able to identify four symptomatic AD studies that have
explored component diffusivities [55–58]. In each of these studies
except one [56] symptomatic AD was associated with increases in DA
(in addition to DR). The DA increases reported were widespread,
prominently affecting not simply medial temporal lobe tracts such
as the fornix and cingulum, but also tracts of temporo-parietal regions
such as the superior longitudinal fasciculus [55,57,58]. Of particular
relevance was the study by Bosch et al. [55], which included an
aMCI group in addition to AD and normal senior groups. These
authors reported that, whereas both patient groups showed DR
increases compared to the normal group, only the AD group showed
DA increases.
In summary, AD-risk and symptomatic AD studies have reported
different patterns of component diffusivity changes. Reported
differences in DR appear to be quantitative, with AD-risk studies
reporting DR increases in a subset of WM tracts showing DR increases
in symptomatic AD. In contrast, reported differences in DA appear to
be qualitative. Whereas AD studies have reported prominent DA
alterations, AD-risk studies have reported little or no DA changes in
any WM tracts. Taken together, ﬁndings from AD-risk and symptom-
atic AD studies are consistent with suggestions that DA increases may
occur at a relatively late stage of WM damage, possibly when ‘cellular
debris’ is cleared by microglia [32,33].10. Relationship to MTL volume
Neuropathology affects the hippocampus and entorhinal cortex
(ERC) early in the course of AD [6,7], and atrophy of these MTL
structures is evident with MR imaging early in the AD disease process
[59–61]. In addition, recent results suggest that smaller MTL volumes
can be detected several years prior to aMCI diagnosis [62,63]. A logical
question is then whether WMmicrostructural changes in presympto-
matic AD are independent of or secondary to classically described gray
matter MTL degeneration.
Of the AD-risk studies conducted to date, three have compared GM
volumes between high and low risk groups. Honea and colleagues [36]
reported reduced GM volume in the hippocampus, amygdala and
precuneus of a high AD-risk group. In contrast, no GM volume re-
ductions were observed in these studies of Gold et al. [38] or Heise et
al. [39]. In our study, we further explored the effects of including
normalized hippocampal volume as a covariate in the group com-
parisons of FA/MD/DR/DA. Including normalized hippocampal
volume as a covariate had minimal effects on the between-group
WM microstructural results and did not alter the ﬁnding of reduced
FA in the fornix in the high AD-risk group. Rather, controlling for
hippocampal volume revealed an additional effect of reduced FA (and
increased DR) in the high AD-risk group in the caudal portion of the
left cingulum, a tract with direct connections between the MTL and
posterior cingulate cortex. The available data suggest that WM
integrity declines do not appear to be a direct consequence of medial
temporal lobe atrophy.11. Neurobiological mechanisms underlying WM
microstructural declines
Little is known about the neurobiological bases of DTI-based WM
integrity declines. Data related to this issue has come from analyses of
DTI-based component diffusivities. The overall pattern observed in
studies conducted to date suggests that AD-risk is associated with
decreased FA and increased DR in the absence of prominent changes
in DA. This pattern of DTI-based ﬁndings is consistent with data
demonstrating that myelin and its components such as cholesterol
and myelin proteins are reduced early in the AD process [64,65] and
with a recently proposed theory suggesting that disruption of myelin
integrity is an early event in the course of AD [66]. Overall, AD-risk
ﬁndings would appear to be inconsistent with a view that Wallerian
degeneration represents the primary mechanism of decreased WM
integrity preceding AD. Wallerian degeneration secondary to distal
cortical atrophy would be most clearly supported by ﬁndings of
signiﬁcant gross tissue loss and decreased DAwhich have not typically
been reported in AD-risk studies.
While reducedWM integrity can exist in the absence of signiﬁcant
gray matter atrophy, it remains possible that microstructural WM
declines may in part reﬂect neuronal dysfunction. For example, the
pattern of WM alterations reported could be due to faulty commu-
nication between neuron and oligodendrocyte. Faulty communication
could be mediated from the axonal side due to neuronal dysfunction,
even in the absence of gross cortical atrophy. This possibility takes
into account the concept that the axon and enveloping myelin make
up an integrated unit via intracellular signaling. The signaling scheme
between axons and investing glia, particularly oligodendroglia in the
CNS, is not yet well deﬁned [67]. However, in the peripheral nervous
system axonal signals are required for myelin maintenance including
PrPc, a putative receptor for beta-amyloid [68]. Alterations in DR from
myelin disruption in tracts projecting from pathologically involved
areas could be reporting neuronal dysfunction through this mecha-
nism at a very early stage, before volume changes are detectable in
GM.
12. Future research
There are a number of caveats related to existing DTI studies of AD-
risk that highlight open questions and motivate future research. First,
only a relatively small number of studies have been conducted. Future
research is required toestablish themost reliableDTI changes associated
with AD risk. Second, DTI research of AD-risk has been limited to cross-
sectional designs. Future prospective studies are required to determine
which DTI based declines actually predict transition to AD. Third, the
inﬂuence of vascular factors on WM integrity declines has not been
systematically explored. Future studies should go beyond excluding
patients with observable hyperintensities by exploring quantitative
relationships between vascular factors and WM integrity. Similarly,
there exists little data concerning the neurobiological bases of WM
integrity declines. Existing data which speak to this issue are largely
limited to DTI analyses of component diffusivities, which are only
suggestive of underlying neurobiological bases (i.e. axonal or myelin
decline). Future research correlating DTI declines with more direct
measures of pathology are required.
13. Conclusions
There is promising data suggesting that WM integrity declines can
be detected in individuals at high AD-risk, prior to cognitive decline.
Tracts showing declines in individuals at high AD-risk involve a subset
of tracts showing decline in symptomatic AD, including WM of the
parahippocampal region, the cingulum, IFOF, and splenium of the
corpus callosum. This network of tracts connects GM structures con-
tributing to memory function such as the MTL, posterior parietal
421B.T. Gold et al. / Biochimica et Biophysica Acta 1822 (2012) 416–422cortex, and inferior frontal cortex. These data suggest that disconnec-
tion of core memory structures represents an early event in the course
of AD. Preliminary evidence of increased radial diffusivity in some
tracts raises the possibility that a myelin-related pathology may
contribute to AD onset, and there is evidence that long association
tracts are affected by this pathology early in the disease process.
However, there is clearly a need for studies correlating DTI metrics
with classic indices of AD pathology such as cerebrospinal ﬂuid
analytes, and brain amyloid burden. Such future studies will help
determine if WM integrity changes reﬂect classic beta-amyloid or
phospho-tau pathologies, or other pathologies more speciﬁcally
related to WM. A greater understanding of the neurobiological bases
of WM microstructural changes associated with AD-risk has the
potential to aid the development of novel pharmacological interven-
tion strategies for AD. For example, one reason that standard
cholinergic therapies may have limited success is that they may be
treating only part of the AD cascade. Future DTI ﬁndings similar to
those described in this review have the potential to spur the
development of additional preventative treatments intended to
protect axon and myelin integrity in seniors at risk of AD.
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